CD47 and neoplasm: Although lymphopenia was observed in peripheral blood of approximately 35% Hu5F9-G4-treated patients (20) it remains unclear whether CD4+ and CD8+ tumor-infiltrating T cells are impacted by prolonged anti-CD47 treatments.